Federal Circuit Delays Delisting of Teva’s Asthma Inhaler Patents Amid Legal Review

The Federal Circuit has decided to postpone the delisting of patents related to a Teva asthma inhaler from the U.S. Food and Drug Administration’s Orange Book. The decision comes after Teva Pharmaceutical Industries Ltd., an Israeli drug manufacturer, argued that such an action could have substantial legal ramifications and warranted a review by the full court. This interim measure highlights ongoing litigation concerns regarding patent listings critical to pharmaceutical companies’ market exclusivity strategies. For more details on this legal development, refer to the coverage by Law360.